World Sleep 2022 | Sleep apnea endotypes and implications for precision sleep medicine
Danny Eckert, PhD, Adelaide Institute for Sleep Health, Flinders University, Adelaide, Australia, explains how improved pathophysiological phenotyping of obstructive sleep apnea (OSA) patients will facilitate precision medicine. Continuous positive airway pressure (CPAP) is associated with poor compliance and is non-tolerable for many OSA patients. Prof. Eckert believes the development of endotype-based treatments such as dental splints, hypoglossal nerve stimulation, and position therapy would better serve patients and could open the door for pharmacotherapy in OSA. This interview was recorded at the World Sleep Congress 2022 in Rome, Italy.
Disclosures
Dr. Eckert is funded by a National Health and Medical Research Council (NHMRC) of Australia Leadership Fellowship. He has also received research grants from Takeda, Bayer, Invicta Medical, Apnimed and a Cooperative Research Centre Grant (collaboration between the Australian Government, Academia and Industry- Industry partner Oventus Medical), and served as a consultant and/or advisory board member for Takeda, Bayer, Invicta Medical, Apnimed and Eisai.
